Get the Stockscreener App
309.24
1.70%
-5.34
Pre-market:
309.69
0.45
+0.15%
Overview
News
Price History
Option Chain
Financials
Why SYK Down?
Discussions
Forecast
Stock Split
Dividend History
Stryker Corp stock is traded at $309.24, with a volume of 2.15M.
It is down -1.70% in the last 24 hours and up +1.49% over the past month.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
See More
Previous Close:
$314.58
Open:
$315.06
24h Volume:
2.15M
Relative Volume:
0.81
Market Cap:
$118.55B
Revenue:
$25.27B
Net Income/Loss:
$3.34B
P/E Ratio:
35.82
EPS:
8.6334
Net Cash Flow:
$4.57B
1W Performance:
-2.28%
1M Performance:
+1.49%
6M Performance:
-13.78%
1Y Performance:
-21.74%
1-Day Range:
$309.12
$316.99
1-Week Range:
$309.12
$335.86
52-Week Range:
$281.00
$404.14
Stryker Corp Stock (SYK) Company Profile
Name
Stryker Corp
Sector
Industry
Phone
(269) 385-2600
Address
1941 STRYKER WAY, PORTAGE, MI
Compare SYK vs ABT, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
309.24 | 118.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
ABT
Abbott Laboratories
|
100.57 | 175.17B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
81.89 | 104.82B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
42.97 | 63.87B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.37 | 48.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Leerink Partners | Outperform |
| Feb-20-26 | Initiated | William Blair | Outperform |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-06-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-19-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Sep-18-25 | Initiated | Rothschild & Co Redburn | Neutral |
| Feb-26-25 | Resumed | Citigroup | Buy |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Outperform |
| May-30-24 | Initiated | Goldman | Neutral |
| May-22-24 | Upgrade | Needham | Hold → Buy |
| Jan-31-24 | Upgrade | Canaccord Genuity | Hold → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-25-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-28-22 | Upgrade | Edward Jones | Hold → Buy |
| Jul-21-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-13-22 | Initiated | Truist | Hold |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-15-22 | Resumed | Evercore ISI | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| Jul-28-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jun-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Oct-06-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-01-20 | Downgrade | Goldman | Buy → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Hold |
| Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-30-19 | Reiterated | BTIG Research | Buy |
| Nov-05-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-30-19 | Reiterated | BofA/Merrill | Buy |
| Jul-02-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-30-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-16-18 | Initiated | BTIG Research | Buy |
| Jun-27-18 | Initiated | Bernstein | Mkt Perform |
| Apr-27-18 | Reiterated | Stifel | Buy |
View All
Stryker Corp Stock (SYK) Latest News
Stryker (SYK) Offers Attractive Valuations Amid Market Shifts - GuruFocus
Stryker stock trades steadily as medical device growth supports valuation - Ad-hoc-news.de
Boston Scientific Settles With Stryker In Spine Device IP Fight - Law360
Top Stock Reports for Qualcomm, Intuitive Surgical & Stryker - Zacks Investment Research
Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Boston Scientific, Stryker Settle Surgical Device Patent Dispute - Bloomberg Law News
Stryker stock trades steadily as recent earnings and growth investments shape outlook - Ad-hoc-news.de
Stryker stock builds on earnings momentum after 16 July 2026 update - Ad-hoc-news.de
Stryker stock trades on its latest reported growth - ad-hoc-news.de
Mako Handheld Robotic Knee System Launch Might Change The Case For Investing In Stryker (SYK) - Yahoo Finance
Is Stryker Corp (SYK) a Bargain After 3.4% Drop? GF Value Says U - GuruFocus
Stryker Corp. stock underperforms Friday when compared to competitors - MarketWatch
Stryker Corp Stock (SYK) Moved Down by 3.42% on Jul 17: A Full Analysis - TradingKey
Stryker stock trades near highs as robotics and trauma growth support valuation - ad-hoc-news.de
Stryker Launches Mako RPS to Expand Robotic Knee Surgery Portfolio - The Globe and Mail
Stryker Corp (XTER:SYK) Stock Price, Trades & News - GuruFocus
Stryker Corp. stock outperforms competitors on strong trading day - MarketWatch
Stryker (SYK) Launches Mako RPS Handheld Robot for Knee Replacem - GuruFocus
Stryker Shares Rise After Commercial Launch of Mako Robotic Power System - Moomoo
Stryker (SYK) Introduces Mako RPS for Total Knee Replacements - GuruFocus
Stryker launches Mako RPS handheld robotic knee system in U.S. - Investing.com
Stryker expands Mako robotics portfolio with full market release of Mako RPS - Finviz
Stryker expands Mako robotics portfolio with full market release of Mako RPS – Company Announcement - Financial Times
Stryker's quarterly earnings preview: What you need to know - MSN
Stryker Corp. stock underperforms Tuesday when compared to competitors - MSN
Stryker Corp (SYK) Stock Down 6.2% -- Now Undervalued? GF Score: 92/100 - GuruFocus
Goldman Sachs Adjusts Price Target on Stryker to $339 From $363, Maintains Neutral Rating - Moomoo
Stryker Corp Stock (SYK) Moved Down by 5.49% on Jul 14: A Full Analysis - TradingKey
Fund Update: 43,404 STRYKER (SYK) shares added to Douglas Lane & Associates, LLC portfolio - Quiver Quantitative
Stryker Slides As Investors Reassess Cyberattack Recovery Ahead Of Q2 Results - Quiver Quantitative
RBC Capital Maintains Stryker Corp(SYK.US) With Buy Rating, Maintains Target Price $435 - Moomoo
BTIG Research Adjusts Stryker Price Target to $371 From $379, Maintains Buy Rating - Moomoo
Piper Sandler reiterates Stryker stock rating on Mako strength - Investing.com
Piper Sandler reiterates Stryker stock rating on Mako strength By Investing.com - Investing.com Canada
Stryker Corp Stock Operating Data - GuruFocus
Stryker Corp (FRA:SYK0) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Stryker (FRA:SYK0) Interest Paid - GuruFocus
Stryker Corp (FRA:SYK0) Competitors 2026 - GuruFocus
Stryker Corp (FRA:SYK0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Stryker Corp (FRA:SYK0) Stock Price & 30 Year Financial Data - GuruFocus
Stryker Corp (FRA:SYK0) Valuation: Modestly Undervalued - GuruFocus
FRA:SYK0 Dividend: Does Stryker Corp Pay a Dividend? - GuruFocus
Stryker Corp (FRA:SYK0) Stock Earnings Transcripts - GuruFocus
Stryker Corp Stock Warning Signs - GuruFocus
Who's Buying or Selling Stryker Corp (FRA:SYK0) Stock Today? - GuruFocus
Stryker Corp (FRA:SYK0) Stock News, Headlines & Updates - GuruFocus
Argus raises Stryker stock price target on cyberattack recovery By Investing.com - Investing.com Australia
Argus raises Stryker stock price target on cyberattack recovery - Investing.com
Inside medtech’s cameo run on HBO Max’s ‘The Pitt’ - Modern Healthcare
Argus Research Maintains Stryker Corp(SYK.US) With Buy Rating, Cuts Target Price to $370 - Moomoo
Stryker's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Stryker Corp Stock (SYK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):